Large Molecule Quantification
Address the quantification of peptide- and protein-based biotherapeutics and biomarkers.
High Resolution Mass Spectrometry for Quantitative and Qualitative (Quant/Qual) Bioanalysis of Antibody-based Therapeutics using Intact mAb and Subunit Detection
High Resolution Mass Spectrometry for Quantitative and Qualitative (Quant/Qual) Bioanalysis of Antibody-based Therapeutics using Intact mAb and Subunit Detection
John T. Mehl, Ph.D Sr. Research Investigator, Bioanalytical Research Bristol-Myers Squibb
As antibody-based therapeutics become more common and more structurally complex, there is an increased need for more in depth understanding of the in vivo disposition of this class of drug modality. This presentation provides an overview of affinity sample preparation and highlight examples of how both Intact and subunit mAb bioanalysis provides insight into the in vivo disposition of antibody-based therapeutics.
Developing bioanalytical assays and workflows for peptide/protein biomarkers and biotherapeutics: Getting the right assay the first time
Developing bioanalytical assays and workflows for peptide/protein biomarkers and biotherapeutics: Getting the right assay the first time
Matt Szapacs, Ph.D Group Leader Exploratory Biomarker Assay Group GlaxoSmithKline
In recent years the use of LC-MS technologies for the quantitation of peptide/protein biomarkers has increased dramatically. This presentation focuses on case studies highlighting the use of systematic method development strategies for both intact analysis and methods involving digestion. In addition, instrument selection (High resolution vs. QQQ) will be highlighted.
A Powerful Hybrid IA-LC-MS/MS Method for Routine Quantification of Insulin Analogues and their Biosimilars in Clinical Trial Samples
A Powerful Hybrid IA-LC-MS/MS Method for Routine Quantification of Insulin Analogues and their Biosimilars in Clinical Trial Samples
Michael Blackburn, M.Phil Bioanalytical Scientist, Method Development Specialist ARCINOVA
Mass spectrometry based assays are rapidly becoming the gold standard for the analysis of insulin biosimilars, and are increasingly requested by regulatory authorities during clinical trials for new diabetic therapies, due to their superior specificity. In this presentation, we show how the sensitivity of the Xevo TQ-XS combined with immunoaffinity extraction and UPLC enables bioanalysts to bring new compounds to market.
- 1 of 7
- next ›